LLY - Eli Lilly And Co
Executive Summary
Eli Lilly And Co (LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets human medicines across diabetes, obesity, oncology, immunology and neuroscience. The Indianapolis-based group is one of the largest pharmaceutical companies by market capitalisation, with a particularly dominant position in the incretin (GLP-1 and GIP/GLP-1) therapeutic class through Mounjaro, Zepbound and Trulicity. The company is listed on the New York Stock Exchange under the ticker LLY and reports in US dollars.
The investment case rests on continued execution of the incretin franchise, sustained growth in oncology, and the integration of recent licensing and bolt-on transactions. The most significant near-term catalyst is the Q3 2026 earnings call scheduled for 29 October 2026, alongside the continued read-out of label-expansion and supply-capacity data points that determine the trajectory of net realised price across the GLP-1 portfolio. The principal risk is that inadequately regulated compounding of incretin products erodes net realised price, diverts prescription volume and damages brand reputation.
BUY. Conviction Score: 76/100. The view would shift towards a less constructive stance if compounded incretin supply became entrenched in the US channel, if tirzepatide volume growth materially decelerated against capacity additions, or if a serious safety signal emerged from a phase 3 oncology or neuroscience readout.
Thesis break: Sustained, regulatorily tolerated compounded tirzepatide supply that materially erodes US net realised price, combined with tirzepatide volume growth decelerating below 20% year on year for two consecutive quarters.
Business Model
Eli Lilly generates revenue primarily through the sale of prescription pharmaceutical products to wholesalers, distributors, retailers and, increasingly, direct-to-patient channels in the United States and other major markets. The portfolio is anchored by the incretin franchise (Mounjaro and Zepbound, both based on tirzepatide, and Trulicity/dulaglutide), which has become the single largest growth engine following demonstrated double-digit volume gains and high-single-digit net price realisation. The oncology franchise contributes meaningful revenue through Verzenio, Jaypirca and earlier-stage assets, while legacy diabetes products (Humalog insulin, Jardiance via the Boehringer Ingelheim alliance) and immunology assets such as Omvoh provide diversification outside incretins.
The core competitive moat is a combination of manufacturing scale for biologic peptides, a deep clinical pipeline built around the dual GIP/GLP-1 mechanism, and a research engine that has produced multiple first- or best-in-class candidates. The company has indicated revenue growth of 49.6% on a trailing basis with net income growth of 93.6% over the same period, reflecting operating leverage on the incretin franchise. Margins remain supported by a mix-shift towards higher-priced specialty biologics, partially offset by heavy capital investment in parenteral manufacturing capacity in Indiana, North Carolina and Ireland.
Beyond internal discovery, Eli Lilly has supplemented the pipeline with disciplined external transactions. The research data flags a USD 100 million InnoCare agreement, a Haisco licensing arrangement, and M&A activity exceeding USD 20 billion, all of which extend capability into oncology, immunology and earlier-stage modalities. The model is therefore best characterised as a vertically integrated, R&D-led pharmaceutical business with material near-term dependence on the incretin category and a longer tail of pipeline optionality in oncology and neuroscience.
Financial Snapshot
Recent Catalysts
[Q1 2026] - On 5 August 2026 Eli Lilly held its Q1 2026 earnings call, providing commentary on volume momentum and capacity build-out for the incretin franchise during the prior quarter. Source: Eli Lilly investor relations.
[Q2 2026] - Eli Lilly is scheduled to report its Q2 2026 results and host its earnings call on 29 October 2026 at 10:00 AM EDT, the next formal financial update for the franchise. Source: Eli Lilly investor relations.
[4 May 2026] - The board of directors of Eli Lilly declared a cash dividend of USD 1.73 per share for the second quarter of 2026, with an ex-dividend date of 15 May 2026, reinforcing the company's progressive capital return programme. Source: PR Newswire (company press release).
[April 2026] - A peer-reviewed publication in the New England Journal of Medicine (Nicholls et al., December 2025) reported cardiovascular outcomes data for tirzepatide versus dulaglutide in type 2 diabetes, supporting potential label expansion. Source: New England Journal of Medicine (PubMed citation 41406444).
[2024 - 2026] - A series of strategic transactions, including a USD 100 million agreement with InnoCare, a Haisco licensing arrangement, and M&A activity exceeding USD 20 billion in aggregate, has been disclosed across recent filings, broadening the pipeline into oncology, immunology and earlier-stage modalities. Source: Company filings and press releases (aggregate).
Thesis Evaluation
Bull Case (44% weight)
The incretin franchise compounds at or above current growth rates, oncology assets deliver at least one transformative read-out over the next 12 months, and bolt-on M&A is integrated without margin dilution. Compounding risk is contained through enforcement action and supply ramp. A bull-case 12-month target of 1320 reflects continued multiple support and earnings upside.
Base Case (51% weight)
Tirzepatide volume continues to grow double-digit, realised net price stabilises after compounding pressure, and the broader portfolio grows in line with consensus. The base-case 12-month target is 1180, only modestly above the current price, reflecting valuation already capturing much of the growth.
Bear Case (5% weight)
Compounded incretin supply becomes entrenched in the US channel, realised net price erodes materially, and capacity additions outrun demand, compressing margins. A bear-case 12-month target of 860 captures a derating alongside earnings risk.
Key Risks
- Incretin compounding erodes net price and share: Compounded versions of tirzepatide and semaglutide continue to circulate in the US, eroding realised price and diverting prescriptions away from the branded portfolio. Estimated probability: 35%. Impact: severe.
- Manufacturing capacity outruns demand: Heavy investment in parenteral biologics capacity could outpace prescription demand if obesity market growth slows, leading to operating deleverage. Estimated probability: 25%. Impact: moderate.
- Pipeline disappointment in oncology or neuroscience: A negative phase 3 readout in a key oncology or Alzheimer's programme would remove meaningful pipeline optionality and pressure the multiple. Estimated probability: 15%. Impact: severe.
- Reimbursement and access headwinds: Payer formularies and government programmes expand step therapy, prior authorisation or price-negotiation pressure on incretins and other key franchises. Estimated probability: 40%. Impact: moderate.
- Large-scale dilutive M&A: Continued transformational M&A in excess of the USD 20 billion already executed could pressure near-term earnings and integration risk. Estimated probability: 30%. Impact: moderate.
- Competitive entry from oral GLP-1 and dual agonists: Rival oral GLP-1 or next-generation dual agonists reach the market faster than expected, fragmenting the obesity opportunity. Estimated probability: 30%. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: long-term growth investors with a minimum five-year holding horizon, a high tolerance for valuation volatility, and a portfolio that can absorb a single position of meaningful size. The stock is suited to investors who understand pharmaceutical pipeline risk, can tolerate drawdowns of 25% or more around regulatory and earnings events, and want exposure to the incretin category and the wider obesity treatment opportunity. The profile also fits income-and-growth investors who are comfortable with the modest current dividend yield and prioritise capital appreciation.
Avoid if: investors require current income, have a short-term horizon of under 24 months, or cannot tolerate a high forward P/E around 27x. Conservative investors with low risk tolerance, those constrained to low-volatility mandates, and investors uncomfortable with regulatory risk in pharmaceuticals should not hold this name. Speculative investors seeking near-term price catalysts in days or weeks should also look elsewhere given the binary nature of clinical and regulatory outcomes.
Recommendation
BUY - 76/100. The BUY tier is supported by concrete catalysts including label expansions, M&A integration, and continued volume momentum in tirzepatide, alongside a strong balance sheet and progressive capital return. The call would be upgraded towards a more constructive stance on durable resolution of the compounding overhang, a positive read-out from a late-stage oncology or neuroscience trial, or evidence that net price has stabilised. The call would be downgraded to a less constructive stance on entrenched compounded supply, material margin compression from capacity under-utilisation, or a transformative dilutive transaction that undermines the franchise growth profile. At the current price of $1425.55 the shares trade at or above our base-case target of $1180.00: the base case is fully priced, existing holders should consider trimming, and new positions are not advised above $966.67.
The probability-weighted value across our three scenarios is $1225.60, 14% below the current price of $1425.55 - the market is currently pricing the shares ahead of our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $966.67 - below this level the upside to the base-case target ($1180.00) is at least 2x the downside to the bear case ($860.00), the minimum risk/reward we require before committing new capital.
between $966.67 and $1180.00 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $1180.00 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 44%.
if sustained, regulatorily tolerated compounded tirzepatide supply that materially erodes US net realised price, combined with tirzepatide volume growth decelerating below 20% year on year for two consecutive quarters, regardless of price - the bear target of $860.00 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 76/100. Trend versus prior report: Initiation.
| Report date | Conviction |
|---|---|
| 2026-10-04 | 76 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow, company earnings presentations, regulatory filings, investor day materials, and analyst commentary drawn from financial news wires, primary company disclosure channels, and conference call transcripts.
Primary source types: SEC filings, earnings call transcripts, press releases, company investor relations materials, regulatory announcements, and peer-reviewed scientific publications indexed via PubMed.
Key sources
- Eli Lilly and Company (LLY) Earnings Date and Reports 2026 $LLY
- Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance | Eli Lilly and Company
- Eli Lilly and Company (LLY) Stock Price, News, Quote & History - Yahoo Finance
- Press Releases | News | Eli Lilly and Company
- Eli Lilly and Company (LLY) Stock Price, Quote, News & Analysis | Seeking Alpha
- Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress | Eli
- Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
- Eli Lilly and Company signs $100 Million contract (September 2026)
- Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals | Reuters
- Eli Lilly Commits Over $20 Billion to Acquisitions in 2026 Expansion Drive - Bloomberg
Analysis generated 2026-10-04. Market data as of 2026-11-12.